SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA grants QIDP Designation to Venus Remedies’ investigational product VRP-034

17 Apr 2025 Evaluate

United States Food and Drug Administration (USFDA) has granted Qualified Infectious Disease Product (QIDP) Designation to Venus Remedies’ investigational product VRP-034, for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults. 

Developed by Venus Medicine Research Centre (VMRC), the R&D division of Venus Remedies, VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to address the nephrotoxic effects associated with conventional polymyxin B therapy. The QIDP designation, granted under the Generating Antibiotic Incentives Now (GAIN) Act. provides VRP-034 with significant regulatory benefits, including priority review, eligibility for fast-track designation, and an additional five years of market exclusivity upon approval in the United States. This recognition by USFDA strengthens Venus Remedies’ commitment to innovation in the fight against AMR and underlines the company’s dedication to addressing unmet needs in infectious disease therapy. 

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.


Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×